Discover the new Chem-Impex: Where innovation starts with a bond.

Catalog Number:
42182
CAS Number:
940310-85-0
NVP-BHG 712
Purity:
≥ 98% (HPLC)
Synonym(s):
4-Methyl-3-[[1-methyl-6-(3-pyridinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide
Hazmat
Documents
$165.65 /10MG
Pack Size Availability Price
Request Bulk Quote
Product Information
Synonyms
4-Methyl-3-[[1-methyl-6-(3-pyridinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide
CAS Number
940310-85-0
Purity
≥ 98% (HPLC)
Molecular Formula
C26H20F3N7O
Molecular Weight
0
MDL Number
MFCD20272929
PubChem ID
16747388
Appearance
White, light yellow or light red powder or crystals
Conditions
Store at ≤ -10 °C
General Information
Synonyms
4-Methyl-3-[[1-methyl-6-(3-pyridinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide
CAS Number
940310-85-0
Purity
≥ 98% (HPLC)
Molecular Formula
C26H20F3N7O
Molecular Weight
0
MDL Number
MFCD20272929
PubChem ID
16747388
Appearance
White, light yellow or light red powder or crystals
Conditions
Store at ≤ -10 °C
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
Yes
Antibiotic
No
DEA-regulated
No
Warnings
-
Applications

NVP-BHG 712 is widely utilized in research focused on

  • Cancer Treatment: This compound is being explored for its potential in targeting specific cancer cells, offering a promising avenue for developing more effective therapies with fewer side effects compared to traditional treatments.
  • Drug Development: Researchers are investigating NVP-BHG 712 as a lead compound in the development of new pharmaceuticals, particularly in the field of oncology, where it may enhance the efficacy of existing drugs.
  • Biochemical Research: The compound serves as a valuable tool in biochemical studies, helping scientists understand the mechanisms of cancer cell proliferation and resistance, which is crucial for advancing treatment strategies.
  • Targeted Therapy: Its ability to selectively inhibit certain pathways in cancer cells makes it a candidate for targeted therapy, potentially leading to more personalized treatment options for patients.
  • Combination Therapies: NVP-BHG 712 is being studied in combination with other agents to evaluate synergistic effects, which could improve overall treatment outcomes and reduce the likelihood of resistance.

Citations